[1]
|
Forouzanfar, M.H., Liu, P., Roth, G.A., et al. (2017) Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA, 317, 165-182. https://doi.org/10.1001/jama.2016.19043
|
[2]
|
Mills, K.T., Stefanescu, A. and He, J. (2020) The Global Epidemiology of Hypertension. Nature Reviews Nephrology, 16, 223-237. https://doi.org/10.1038/s41581-019-0244-2
|
[3]
|
Whelton, P.K., Carey, R.M., Aronow, W.S., et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiolo-gy/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiol-ogy, 71, e127-e248.
https://doi.org/10.1161/HYP.0000000000000076
|
[4]
|
张跃, 李宁, 邱健, 等. 血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦治疗高血压的研究进展[J]. 中华高血压杂志, 2021, 29(6): 519-524.
|
[5]
|
Agita, A. and Alsagaff, M.T. (2017) Inflammation, Immunity, and Hypertension. Acta Medica Indonesiana, 49, 158-165.
|
[6]
|
Idris-Khodja, N., Mian, M.O., Paradis, P., et al. (2014) Dual Opposing Roles of Adaptive Immunity in Hypertension. European Heart Journal, 35, 1238-1244. https://doi.org/10.1093/eurheartj/ehu119
|
[7]
|
中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56.
|
[8]
|
Iglesias-Garriz, I., Olalla-Gómez, C., Garrote, C., et al. (2012) Contribution of Right Ventricular Dysfunction to Heart Failure Mortality: A Meta-Analysis. Reviews in Cardiovascular Medicine, 13, e62-e69.
https://doi.org/10.3909/ricm0602
|
[9]
|
Williams, B., Mancia, G., Spiering, W., et al. (2018) 2018 ESC/ESH Guide-lines for the Management of Arterial Hypertension. European Heart Journal, 39, 3021-3104. https://doi.org/10.1093/eurheartj/ehy339
|
[10]
|
Ettehad, D., Emdin, C.A., Kiran, A., et al. (2016) Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis. The Lancet, 387, 957-967.
https://doi.org/10.1016/S0140-6736(15)01225-8
|
[11]
|
郑丽, 张续乾, 孙雪林, 等. 沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析[J]. 中国药物警戒, 2022, 19(10): 1118-1122+1135.
|
[12]
|
Bavishi, C., Messerli, F.H., Kadosh, B., et al. (2015) Role of Neprilysin Inhibitor Combinations in Hypertension: Insights from Hypertension and Heart Failure Trials. European Heart Journal, 36, 1967-1973.
https://doi.org/10.1093/eurheartj/ehv142
|
[13]
|
Ruilope, L.M., Dukat, A., Böhm, M., et al. (2010) Blood-Pressure Reduction with LCZ696, a Novel Dual-Acting Inhibitor of the Angiotensin II Receptor and Neprilysin: A Randomised, Double-Blind, Placebo-Controlled, Active Comparator Study. The Lancet, 375, 1255-1266. https://doi.org/10.1016/S0140-6736(09)61966-8
|
[14]
|
Kario, K., Sun, N., Chiang, F.T., et al. (2014) Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients with Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study. Hypertension (Dallas, Tex: 1979), 63, 698-705. https://doi.org/10.1161/HYPERTENSIONAHA.113.02002
|
[15]
|
Rakugi, H., Kario, K., Yamaguchi, M., et al. (2022) Efficacy of Sacubitril/Valsartan versus Olmesartan in Japanese Patients with Essential Hypertension: A Random-ized, Double-Blind, Multicenter Study. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 45, 824-833. https://doi.org/10.1038/s41440-021-00819-7
|
[16]
|
Kario, K. (2018) The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Current Cardiology Reports, 20, 5.
https://doi.org/10.1007/s11886-018-0944-4
|
[17]
|
Nielsen, P.M., Grimm, D., Wehland, M., et al. (2018) The Com-bination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure—An Update. Basic & Clinical Pharmacology & Toxicology, 122, 9-18.
https://doi.org/10.1111/bcpt.12912
|
[18]
|
D’elia, E., Iacovoni, A., Vaduganathan, M., et al. (2017) Neprilysin Inhibi-tion in Heart Failure: Mechanisms and Substrates beyond Modulating Natriuretic Peptides. European Journal of Heart Failure, 19, 710-717.
https://doi.org/10.1002/ejhf.799
|
[19]
|
Böhm, M., Young, R., Jhund, P.S., et al. (2017) Systolic Blood Pressure, Cardiovascular Outcomes and Efficacy and Safety of Sacubitril/Valsartan (LCZ696) in Patients with Chronic Heart Fail-ure and Reduced Ejection Fraction: Results from PARADIGM-HF. European Heart Journal, 38, 1132-1143. https://doi.org/10.1093/eurheartj/ehw570
|
[20]
|
Hubers, S.A. and Brown, N.J. (2016) Combined Angiotensin Re-ceptor Antagonism and Neprilysin Inhibition. Circulation, 133, 1115-1124. https://doi.org/10.1161/CIRCULATIONAHA.115.018622
|
[21]
|
Mcmaster, W.G., Kirabo, A., Madhur, M.S., et al. (2015) Inflammation, Immunity, and Hypertensive End-Organ Damage. Circulation Research, 116, 1022-1033. https://doi.org/10.1161/CIRCRESAHA.116.303697
|
[22]
|
Karbach, S., Croxford, A.L., Oelze, M., et al. (2014) In-terleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 2658-2668. https://doi.org/10.1161/ATVBAHA.114.304108
|
[23]
|
Nguyen, H., Chiasson, V.L., Chatterjee, P., et al. (2013) In-terleukin-17 Causes Rho-Kinase-Mediated Endothelial Dysfunction and Hypertension. Cardiovascular Research, 97, 696-704. https://doi.org/10.1093/cvr/cvs422
|
[24]
|
Zhou, G., Cheung, A.K., Liu, X., et al. (2014) Valsartan Slows the Progression of Diabetic Nephropathy in db/db Mice via a Reduction in Podocyte Injury, and Renal Oxidative Stress and Inflammation. Clinical Science (London), 126, 707-720. https://doi.org/10.1042/CS20130223
|
[25]
|
Mohany, M., Alanazi, A.Z., Alqahtani, F., et al. (2020) LCZ696 Mitigates Diabetic-Induced Nephropathy through Inhibiting Oxi-dative Stress, NF-κB Mediated Inflammation and Glomerulosclerosis in Rats. PeerJ, 8, e9196.
https://doi.org/10.7717/peerj.9196
|
[26]
|
Liang, W., Xie, B.K., Ding, P.W., et al. (2021) Sacubitril/Valsartan Allevi-ates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 In-flammasome Pathway. Frontiers in Pharmacology, 12, Article ID: 727838. https://doi.org/10.3389/fphar.2021.727838
|